All News

Do consumers pay attention to risk information in television ads? FDA plans to find out with a study using phony ads for a nonexistent blood pressure drug.

Crohn?s disease is the topic of conversation on the first Abbott unbranded podcast. The company talks about why it went the radio route.

Whether or not BMS's $4.5 billion offer for ImClone is fair is up in the air, but either way BMS stands to gain chunk of change if its bid is approved.

A new study reports that more than 27 percent of Americans are not being treated for HIV because they fear adverse reactions to the drugs. Pharm Exec talked to the doctors in charge of the survey to learn more.

FDA's new sentinel system shows the pendulum swing toward safety won't swing back anytime soon

FDA preemption is a hot issue for pharma, and it's likely to get hotter. But it's the wrong issue.

There's a cure for everything, as long as the patient is a mouse

Glaxo launched a YouTube page targeting potential employees through YouTube. One video in particular features CEO Andrew Witty talking about his adventures in GSK. Is this the future of recruitment?

After years of owning a majority share in Genentech, Roche makes a play to buy out the rest of the biotech firm.

Bristol-Meyers Squibb will pay more than half a billion dollars to settle charges that it illegally promoted the sale of the anti-psychotic drug Abilify for off-label uses.

Pfizer, Schering, Abbott, and Boehringer announced that they will be shifting and slashing staff at both sales and manufacturing levels. While much smaller in scope than earlier cuts, the bloodletting doesn?t seem to be over.

The new Phrma marketing code bans pens and pads and other non-educational gifts. It bans dinners with docs (but not the lunch-and-learn). And it requires compliance. Are we safer yet?

The Johnson & Johnson subsidiary launched an unbranded support group page on social networking site Facebook giving moms of kids with ADHD a place to learn, but not a place to converse.

Johnson & Johnson launched its healthcare video channel on Google?s YouTube, signaling pharma?s further entrenchment into the online community

Fresenius snagged injectible manufacturer APP Pharmaceuticals in a $3.7 billion cash deal. Along with entry into the US market, Fresenius also gets access to one of the largest suppliers of heparin.

A new global CEO study examines what near- and long-term changes pharma leaders expect to face and in what areas they are planning to focus their attention. Key focus areas: global business design and new markets.

With the launch of the Center for Communication Compliance, pharma companies and PR firms have a one-stop resource to educate themselves about marketing regulations in an effort to reduce accidental non-compliance.

Rejection is tough to take, but leaders have the drive and ability to bounce back from a setback with boundless energy

It's not that I disagree with the Obama and McCain healthcare proposals. It's that there's nothing actually there to disagree with

Rare disease treatments are riding high as patient adcovates, pharma companies, and government officials celebrate the ODA's 25th anniversary

Genentech had previously been number one by a very wide margin. This year, that margin started to narrow. Novartis is now a much closer second

No, it's not as glamorous as its double-helixed offspring. But recent revelations about RNA turn even cold-eyed scientists into lyrical romantics

A new European Federation of Industries and Associations report expresses industry fears after Neelie Kroes's January raids.

Merck bolsters vaccine making division with the addition of 400 new employees to fill its new manufacturing plant.

On Monday, a handful of Big Pharma companies told Congress that they would put a six-month moratorium on drug ads for recently approved medication. Pfizer, Merck, Schering-Plough, and Johnson & Johnson also agreed to closely follow the American Medical Association's guidelines when using actors playing physicians in advertisements.

The American Medical Association's proposal to keep pharma from funding CME programs was put on hold for further review. But don?t expect the plan to disappear for good.

French drugmaker to cut 800 jobs, joining the long list of companies restructuring to make ends meet.

Swiss pharma giant Roche was abuzz at ADA, announcing that its new diabetes treatment is set for Phase III trials and commenting on future plans for failed CETP inhibitor dalcetrapib.

Prix Galien USA - The Galen Prize - Gala Awards Ceremony